PubRank

Antonio Colombo

Author PubWeight™ 9.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Eur Heart J 2014 2.31
2 Transapical versus transfemoral aortic valve implantation: a multicenter collaborative study. Ann Thorac Surg 2013 2.14
3 Smoking is associated with adverse clinical outcomes in patients undergoing revascularization with PCI or CABG: the SYNTAX trial at 5-year follow-up. J Am Coll Cardiol 2015 1.56
4 Short-term and long-term clinical impact of stent thrombosis and graft occlusion in the SYNTAX trial at 5 years: Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery trial. J Am Coll Cardiol 2013 0.81
5 Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J 2017 0.79
6 Comparison of percutaneous coronary intervention (with drug-eluting stents) versus coronary artery bypass grafting in women with severe narrowing of the left main coronary artery (from the Women-Drug-Eluting stent for LefT main coronary Artery disease Registry). Am J Cardiol 2014 0.78
7 Modified contrast microinjection technique to facilitate chronic total occlusion recanalization. Catheter Cardiovasc Interv 2015 0.77
8 Transcatheter aortic valve implantation in patients with severe aortic valve stenosis and large aortic annulus, using the self-expanding 31-mm Medtronic CoreValve prosthesis: first clinical experience. J Thorac Cardiovasc Surg 2013 0.75
9 Transcatheter valve interventions: playground for cardiologists or cardiac surgeons? The cardiologist's view. EuroIntervention 2015 0.75
10 TCT-222 Clinical Outcomes of Dual Antiplatelet Therapy after Coronary Stenting in Patients with Chronic Kidney Disease: Patient-level Meta-analysis of 4 Randomized Clinical Trials. J Am Coll Cardiol 2016 0.75
11 Corrigendum to "Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-year final clinical outcomes from the MASCOT post-marketing registry" [Int. J. Cardiol. 283 (2019) 67-72]. Int J Cardiol 2019 0.75
12 Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials. Catheter Cardiovasc Interv 2016 0.75
13 Transfemoral transcatheter aortic valve implantation in patients with small diseased peripheral vessels. Cardiovasc Revasc Med 2015 0.75
14 TCT-66 Effects of dual antiplatelet therapy cessation among patients with diabetes mellitus after PCI with DES. J Am Coll Cardiol 2016 0.75
15 TCT-265 One-year Outcome of Polymer-free Amphilimus-eluting Stent versus Biodegradable Polymer Biolimus-eluting Stent in Diabetes Mellitus Patients. Propensity-Matched Analysis of the ASTUTE (AmphilimuS iTalian mUlticenTre rEgistry) and INSPIRE-1 (Italian Nobori Stent ProspectIve REgistry-1) Registries. J Am Coll Cardiol 2016 0.75
16 A novel maneuver to facilitate retrograde wire externalization during retrograde chronic total occlusion percutaneous coronary intervention. Catheter Cardiovasc Interv 2016 0.75
17 TCT-206 Tailoring the Intensity of Antiplatelet Pharmacotherapy to Ischemic and Bleeding Risk: A Cost Optimizing Simulation From PARIS. J Am Coll Cardiol 2016 0.75
18 TCT-229 Safety and Efficacy of Rotational Atherectomy for the Treatment of Undilatable Underexpanded Stents Implanted in Calcific Lesions. J Am Coll Cardiol 2016 0.75
19 TCT-698 Comparison of the fully repositionable and retrievable Lotus Valve and Direct Flow Medical Valve for the treatment of severe aortic stenosis: a high-volume single center experience. J Am Coll Cardiol 2016 0.75
20 TCT-361 Targeting Transradial Approach: an Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol 2016 0.75
21 TCT-211 Incidence and Impact of Dual Antiplatelet Therapy Cessation on Clinical Outcomes in Patients with Renal Dysfunction: Insights from the PARIS Registry. J Am Coll Cardiol 2016 0.75
22 TCT-204 Optimal duration of dual antiplatelet therapy (DAPT) after second generation drug-eluting stent (DES) implantation in elderly patients: the SECURITY-ELDERLY substudy. J Am Coll Cardiol 2016 0.75
23 Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. J Am Coll Cardiol 2017 0.75
24 A double-blind randomised study to evaluate the efficacy and safety of bindarit in preventing coronary stent restenosis. EuroIntervention 2016 0.75
25 Right ventricular evaluation to improve survival outcome in patients with severe functional mitral regurgitation and advanced heart failure undergoing MitraClip therapy. Int J Cardiol 2016 0.75
26 TCT-437 Clinical outcome of coronary bifurcation management with a "fully bioresorbable" technique. Results of the multicentre BBS study. J Am Coll Cardiol 2016 0.75
27 TCT-506 Coronary sinus reduction improves myocardial perfusion reserve index assessed by dipyridamole stress cardiac magnetic resonance. J Am Coll Cardiol 2016 0.75
28 Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thromb Haemost 2019 0.75
29 A challenging case of transcatheter aortic prosthesis dysfunction: Endocarditis or thrombosis? Int J Cardiol 2016 0.75
30 TCT-351 Coronary sinus reducer implantation for the treatment of chronic refractory angina: a single center experience. J Am Coll Cardiol 2016 0.75
31 TCT-436 Multi-Center, Post-marketing Evaluation of the Elixir DESolve® Novolimus Eluting Bioresorbable Coronary Stent System: 6-month Results from the DESolve PMCF Study. J Am Coll Cardiol 2016 0.75
32 TCT-41 Up to two years follow up results of mitral valve transcatheter annuloplasty system for mitral reconstruction multi-center trial. J Am Coll Cardiol 2016 0.75
33 TCT-85 Prevalence of tricuspid regurgitation and its impact on mid-term outcomes: insights from a tertiary referral center. J Am Coll Cardiol 2016 0.75